Related Experiment Video
Updated: Dec 13, 2025
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
Current Status and Future Perspectives of Checkpoint Inhibitor Immunotherapy for Prostate Cancer: A Comprehensive
1Department of Urology, C.H.A. Bundang Medical Center, University College of Medicine, Seongnam 13496, Korea.
Abstract:
The clinical spectrum of prostate cancer (PCa) varies from castration-naive to metastatic castration-resistant disease. Despite the administration of androgen synthesis inhibitors and chemotherapy regimens for castration-resistant prostate cancer, the treatment options for this entity are limited. The utilization of the immune system against cancer cells shows potential as a therapeutic modality for various solid tumors and hematologic malignancies. With technological advances over the last decade, immunotherapy has become an integral treatment modality for advanced solid tumors. The feasibility of immunotherapy has shown promise for patients with PCa, and with advances in molecular diagnostic platforms and our understanding of immune mechanisms, immunotherapy is reemerging as a potential treatment modality for PCa. Various combinations of individualized immunotherapy and immune checkpoint blockers with androgen receptor-targeted therapies and conventional cytotoxic agents show promise. This article will review the current status of immunotherapy, including new discoveries and precision approaches to PCa, and discuss future directions in the continuously evolving landscape of immunotherapy.
Insights
Immunotherapy shows promise for advanced prostate cancer (PCa) treatment. Combining immune strategies with other therapies offers new hope for patients with limited options.
Area of Science:
- Oncology
- Immunology
- Urology
Background:
- Prostate cancer (PCa) presents a spectrum from castration-naive to metastatic castration-resistant disease.
- Current treatments for castration-resistant prostate cancer, including androgen synthesis inhibitors and chemotherapy, have limitations.
- Immunotherapy harnesses the immune system to combat cancer cells, showing potential across various malignancies.
Purpose of the Study:
- To review the current status of immunotherapy for prostate cancer.
- To discuss new discoveries and precision approaches in PCa immunotherapy.
- To explore future directions in the evolving landscape of prostate cancer immunotherapy.
Main Methods:
- Review of current literature on immunotherapy in prostate cancer.
- Analysis of advances in molecular diagnostics and immune mechanisms.
- Examination of combination strategies involving immunotherapy, immune checkpoint blockers, androgen receptor-targeted therapies, and cytotoxic agents.
Main Results:
- Immunotherapy has emerged as a promising therapeutic modality for advanced solid tumors, including prostate cancer.
- Technological advancements have facilitated the integration of immunotherapy into cancer treatment paradigms.
- Individualized immunotherapy and immune checkpoint blockers, when combined with other therapies, show significant promise for PCa.
Conclusions:
- Immunotherapy represents a reemerging and potentially transformative treatment modality for prostate cancer.
- Combination therapies integrating immunotherapy with targeted agents and chemotherapy are key to future treatment strategies.
- Continued research into molecular diagnostics and immune mechanisms will drive precision approaches in PCa immunotherapy.
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...